文献速递肝病

新一代肝纤维化无创检测在MASLD中准确性提高

A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
PubMed 文献 · J Hepatol · 2024-12-13

该研究纳入1051例MASLD患者,比较推荐的无创检测(FIB-4、Fibrotest、FibroMeter、LSM、Elasto-FibroMeter、ELF)对进展期纤维化的准确性,并开发新检测FIB-9、FIB-11、FIB-12。推荐检测准确性均低于80%,新检测准确性提高,FIB-12优于其他检测。

要点

  • 推荐的无创检测对MASLD进展期纤维化准确性均不足80%。
  • 验证集中FIB-12的AUROC为0.912,优于其他检测。
  • FIB-9准确性等于或超过推荐检测,FIB-12准确性83.3%。

核心结论

  • 推荐的无创检测对MASLD进展期纤维化准确性低于80%。
  • 新的无创检测FIB-9、FIB-11、FIB-12进一步提高了准确性。
  • FIB-12优于其他所有无创检测。

研究设计与样本

  • 共纳入1051例MASLD患者,分为推导集637例和验证集414例。
  • 主要结局为Kleiner F3+F4,主要评估准确性。
  • 推荐的无创检测包括FIB-4、Fibrotest、FibroMeter、LSM、Elasto-FibroMeter和ELF,其中ELF在396例患者中评估。
  • 使用机器学习优化的多靶向方法开发新无创检测FIB-9、FIB-11和FIB-12。

主要发现

  • 全人群中推荐无创检测准确性:Fibrotest 68.0%、FIB-4 71.2%、FibroMeter 75.1%、LSM 75.9%、Elasto-FibroMeter 78.6%。
  • 验证集中AUROC:FIB-4 0.757、Fibrotest 0.766、FibroMeter 0.850、LSM 0.852、FIB-9 0.863、FIB-11 0.880、Elasto-FibroMeter 0.894、FIB-12 0.912(p<0.001)。
  • FIB-12的AUROC优于ELF的AUROC(0.906 vs. 0.865,p=0.039)。
  • 验证集准确性:FIB-4 68.8%、Fibrotest 68.6%、LSM 75.4%、FibroMeter 76.3%、FIB-9 78.7%、Elasto-FibroMeter 79.7%、FIB-11 80.2%、FIB-12 83.3%(各无创检测间p<0.001)。
  • FIB-9在68.1%的患者中使用两个cut-off时准确性为85.8%,在71.7%的患者中与FIB-4一致时准确性为83.2%。

关键数值与推荐

  • FIB-9通过免费计算器可用,包含九种常见血液标志物。
  • FIB-11增加了两种专用血液标志物,FIB-12增加了肝脏硬度。
  • FIB-9适合筛查,FIB-11或FIB-12适合诊断。

临床怎么用

  • 推荐的无创检测对MASLD进展期纤维化准确性不足。
  • FIB-9可用于筛查,FIB-11或FIB-12可用于诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The accuracy of non-invasive tests (NITs) should be ≥80% (EASL recommendation). We aimed to compare the accuracies of the recommended NITs for advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) and to develop NITs with improved accuracy. METHODS: A total of 1,051 patients with MASLD were allocated to derivation (n = 637) and validation (n = 414) sets. The main outcome (Kleiner F3+F4) was primarily evaluated by accuracy. Recommended NITs included: FIB-4, Fibrotest, FibroMeter, liver stiffness measurement (LSM by Fibroscan), Elasto-FibroMeter (FibroMeter-LSM combination), and ELF (enhanced liver fibrosis) in 396 patients. We used machine learning-optimized multitargeting to develop new NITs: FIB-9 (including nine common biomarkers), FIB-11 (adding two specialized blood markers) and FIB-12 (adding LSM). RESULTS: In the whole population, the accuracies of recommended NITs were insufficient: Fibrotest, 68.0%; FIB-4, 71.2%; FibroMeter, 75.1%; LSM, 75.9%; Elasto-FibroMeter, 78.6%. Therefore, new NITs (FIB-9, FIB-11, FIB-12) were developed in the derivation set. In the validation set, AUROCs were: FIB-4, 0.757; Fibrotest, 0.766; FibroMeter, 0.850; LSM, 0.852; FIB-9, 0.863; FIB-11, 0.880; Elasto-FibroMeter, 0.894; FIB-12, 0.912 (p <0.001). The FIB-12 AUROC was superior to the ELF AUROC (0.906 vs. 0.865, p = 0.039). Accuracies were: FIB-4, 68.8%; Fibrotest, 68.6%; LSM, 75.4%; FibroMeter, 76.3%; FIB-9, 78.7%; Elasto-FibroMeter, 79.7%; FIB-11, 80.2%; FIB-12, 83.3% (p <0.001 between all NITs). Scores were segmented by ≥90% sensitivity and specificity cut-offs or NIT match, which individualized subgroups with NIT accuracies ≥80%, e.g. for FIB-9: 85.8% in 68.1% of patients using two cut-offs and 83.2% in 71.7% of patients where FIB-9 agreed with FIB-4. CONCLUSIONS: Recommended NITs had accuracies <80% for advanced fibrosis in MASLD. Several NIT segmentations individualized subgroups with accuracies ≥80%. New NITs further improved accuracy. The simple FIB-9 (available via a free calculator) provided accuracy equaling or surpassing recommended NITs. FIB-12 outperformed other NITs. IMPACT AND IMPLICATIONS: Currently recommended non-invasive tests (NITs) have insufficient accuracy (<80%) for the diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, we developed three new NITs with new statistical techniques. Thus, FIB-9 (available via a free calculator), including nine common blood markers, equaled the performance of patented NITs. FIB-11, adding two specialized blood markers, and FIB-12, adding liver stiffness, had accuracy >80%. FIB-12 outperformed all other NITs. FIB-9 is suitable for screening and FIB-11 or FIB-12 for diagnosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Calès P, Canivet CM, Costentin C, et al. A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol. 2024. PMID: 39674323. doi:10.1016/j.jhep.2024.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。